← Human Trials & Peer-Reviewed Studies
Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial.
Plain-language guide to PMID 26277548 (2015): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 30 patients.
Key Facts
- PMID
- 26277548
- Journal
- Clinical immunology (Orlando, Fla.)
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Treiber G et al. (11 authors)
- DOI
- 10.1016/j.clim.2015.08.002
- Registered trial
- NCT01390480
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
It is unknown if cholecalciferol is able to modify defects in regulatory T cells (Tregs) in type 1 diabetes (T1D).
Who Took Part
The abstract describes 30 patients taking part.
The age groups tagged for this paper are children and teenagers, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and pilot study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
Tregs were determined by FACS-analysis and functional tests were assessed with ex vivo suppression co-cultures at months 0, 3, 6 and 12.
What Was Measured
Topics PubMed links to this paper include C-Peptide, Cholecalciferol, Diabetes Mellitus, Type 1, Dietary Supplements, Fasting, Pilot Projects and T-Lymphocytes, Regulatory.
Author keywords: Randomized controlled trial, Regulatory T cells, Suppressive capacity, Type 1 diabetes and Vitamin D.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 30 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2015 (Clinical immunology (Orlando, Fla.)), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.